FDA halts Neumora’s schizophrenia drug trial over convulsions in rabbits
The FDA placed the clinical hold based on the preclinical data that showed that Neumora’s NMRA-266 triggered convulsions in rabbits.
The FDA placed the clinical hold based on the preclinical data that showed that Neumora’s NMRA-266 triggered convulsions in rabbits.
The study will assess the economic and healthcare outcome benefits of Acarix's AI-powered CADScor System compared to traditional stress test.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment...
Cleerly touts new data for AI cardiovascular software
Moderna’s Phase III Covid-19 vaccine trial meets primary endpoints
Gedeon Richter adopts TransPerfect’s trial management solutions
Artificial intelligence identified two evolutionary pathways of prostate cancer